Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer

Yukinori Kurokawa, Takuya Hamakawa, Yasuhiro Miyazaki, Tsuyoshi Takahashi, Makoto Yamasaki, Hiroshi Miyata, Kiyokazu Nakajima, Shuji Takiguchi, Masaki Mori, Yuichiro Doki

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background/Aim: S-1, cisplatin, and docetaxel (DCS) constitute an effective regimen for gastric cancer. We conducted a retrospective cohort study of systemic DCS and a prospective phase I trial of intraperitoneal DCS in the preoperative setting for marginally resectable gastric cancer. Patients and Methods: Under the systemic regimen, patients received cisplatin (60 mg/m2) plus docetaxel (40 mg/m2) intravenously on day 1 and S-1 (80 mg/m2) on days 1-14, of a 28-day cycle. With the intraperitoneal regimen, the schedule for S-1 and cisplatin was the same. Dose escalation for docetaxel started at 30 mg/m2 (level 1). Results: Between August 2010 and July 2013, 26 consecutive patients were treated with the systemic regimen. Grade 3-4 neutropenia occurred in 81% but the toxicity profile was very tolerable. The response rate based on the Response Evaluation Criteria in Solid Tumors (RECIST) was 89%. Between April 2012 and April 2014, 5 patients with linitis plastica, large ulcero-invasive type tumors, positive washing cytology or peritoneal metastasis were enrolled in the phase I trial of the intraper itoneal regimen. Grade 3-4 elevations in aspartate/alanine aminotransferase (AST/ALT) occurred in the first 2 patients. The next 3 patients, who received docetaxel (20 mg/m2) on days 1 and 15 (level 0), had no dose-limiting toxicity. Four patients, including 3 with peritoneal metastasis and/or positive cytology before treatment, underwent R0 resection after intraperitoneal chemotherapy. Conclusion: Our studies revealed the efficacy of the systemic regimen and the safety of the intraperitoneal regimen. Further investigation of these two types of preoperative DCS chemotherapy is warranted.

Original languageEnglish
Pages (from-to)2223-2228
Number of pages6
JournalAnticancer research
Volume35
Issue number4
Publication statusPublished - Apr 1 2015
Externally publishedYes

Fingerprint

docetaxel
Cisplatin
Stomach Neoplasms
Drug Therapy
Cell Biology
Linitis Plastica
Neoplasm Metastasis
Aspartate Aminotransferases
Neutropenia
Alanine Transaminase
Appointments and Schedules
Cohort Studies
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kurokawa, Y., Hamakawa, T., Miyazaki, Y., Takahashi, T., Yamasaki, M., Miyata, H., ... Doki, Y. (2015). Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer. Anticancer research, 35(4), 2223-2228.

Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer. / Kurokawa, Yukinori; Hamakawa, Takuya; Miyazaki, Yasuhiro; Takahashi, Tsuyoshi; Yamasaki, Makoto; Miyata, Hiroshi; Nakajima, Kiyokazu; Takiguchi, Shuji; Mori, Masaki; Doki, Yuichiro.

In: Anticancer research, Vol. 35, No. 4, 01.04.2015, p. 2223-2228.

Research output: Contribution to journalArticle

Kurokawa, Y, Hamakawa, T, Miyazaki, Y, Takahashi, T, Yamasaki, M, Miyata, H, Nakajima, K, Takiguchi, S, Mori, M & Doki, Y 2015, 'Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer', Anticancer research, vol. 35, no. 4, pp. 2223-2228.
Kurokawa, Yukinori ; Hamakawa, Takuya ; Miyazaki, Yasuhiro ; Takahashi, Tsuyoshi ; Yamasaki, Makoto ; Miyata, Hiroshi ; Nakajima, Kiyokazu ; Takiguchi, Shuji ; Mori, Masaki ; Doki, Yuichiro. / Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer. In: Anticancer research. 2015 ; Vol. 35, No. 4. pp. 2223-2228.
@article{7dbc47f2cbec4442937716cb49636dd7,
title = "Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer",
abstract = "Background/Aim: S-1, cisplatin, and docetaxel (DCS) constitute an effective regimen for gastric cancer. We conducted a retrospective cohort study of systemic DCS and a prospective phase I trial of intraperitoneal DCS in the preoperative setting for marginally resectable gastric cancer. Patients and Methods: Under the systemic regimen, patients received cisplatin (60 mg/m2) plus docetaxel (40 mg/m2) intravenously on day 1 and S-1 (80 mg/m2) on days 1-14, of a 28-day cycle. With the intraperitoneal regimen, the schedule for S-1 and cisplatin was the same. Dose escalation for docetaxel started at 30 mg/m2 (level 1). Results: Between August 2010 and July 2013, 26 consecutive patients were treated with the systemic regimen. Grade 3-4 neutropenia occurred in 81{\%} but the toxicity profile was very tolerable. The response rate based on the Response Evaluation Criteria in Solid Tumors (RECIST) was 89{\%}. Between April 2012 and April 2014, 5 patients with linitis plastica, large ulcero-invasive type tumors, positive washing cytology or peritoneal metastasis were enrolled in the phase I trial of the intraper itoneal regimen. Grade 3-4 elevations in aspartate/alanine aminotransferase (AST/ALT) occurred in the first 2 patients. The next 3 patients, who received docetaxel (20 mg/m2) on days 1 and 15 (level 0), had no dose-limiting toxicity. Four patients, including 3 with peritoneal metastasis and/or positive cytology before treatment, underwent R0 resection after intraperitoneal chemotherapy. Conclusion: Our studies revealed the efficacy of the systemic regimen and the safety of the intraperitoneal regimen. Further investigation of these two types of preoperative DCS chemotherapy is warranted.",
author = "Yukinori Kurokawa and Takuya Hamakawa and Yasuhiro Miyazaki and Tsuyoshi Takahashi and Makoto Yamasaki and Hiroshi Miyata and Kiyokazu Nakajima and Shuji Takiguchi and Masaki Mori and Yuichiro Doki",
year = "2015",
month = "4",
day = "1",
language = "English",
volume = "35",
pages = "2223--2228",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Preoperative systemic and intraperitoneal chemotherapy consisting of S-1, cisplatin and docetaxel in patients with marginally resectable gastric cancer

AU - Kurokawa, Yukinori

AU - Hamakawa, Takuya

AU - Miyazaki, Yasuhiro

AU - Takahashi, Tsuyoshi

AU - Yamasaki, Makoto

AU - Miyata, Hiroshi

AU - Nakajima, Kiyokazu

AU - Takiguchi, Shuji

AU - Mori, Masaki

AU - Doki, Yuichiro

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background/Aim: S-1, cisplatin, and docetaxel (DCS) constitute an effective regimen for gastric cancer. We conducted a retrospective cohort study of systemic DCS and a prospective phase I trial of intraperitoneal DCS in the preoperative setting for marginally resectable gastric cancer. Patients and Methods: Under the systemic regimen, patients received cisplatin (60 mg/m2) plus docetaxel (40 mg/m2) intravenously on day 1 and S-1 (80 mg/m2) on days 1-14, of a 28-day cycle. With the intraperitoneal regimen, the schedule for S-1 and cisplatin was the same. Dose escalation for docetaxel started at 30 mg/m2 (level 1). Results: Between August 2010 and July 2013, 26 consecutive patients were treated with the systemic regimen. Grade 3-4 neutropenia occurred in 81% but the toxicity profile was very tolerable. The response rate based on the Response Evaluation Criteria in Solid Tumors (RECIST) was 89%. Between April 2012 and April 2014, 5 patients with linitis plastica, large ulcero-invasive type tumors, positive washing cytology or peritoneal metastasis were enrolled in the phase I trial of the intraper itoneal regimen. Grade 3-4 elevations in aspartate/alanine aminotransferase (AST/ALT) occurred in the first 2 patients. The next 3 patients, who received docetaxel (20 mg/m2) on days 1 and 15 (level 0), had no dose-limiting toxicity. Four patients, including 3 with peritoneal metastasis and/or positive cytology before treatment, underwent R0 resection after intraperitoneal chemotherapy. Conclusion: Our studies revealed the efficacy of the systemic regimen and the safety of the intraperitoneal regimen. Further investigation of these two types of preoperative DCS chemotherapy is warranted.

AB - Background/Aim: S-1, cisplatin, and docetaxel (DCS) constitute an effective regimen for gastric cancer. We conducted a retrospective cohort study of systemic DCS and a prospective phase I trial of intraperitoneal DCS in the preoperative setting for marginally resectable gastric cancer. Patients and Methods: Under the systemic regimen, patients received cisplatin (60 mg/m2) plus docetaxel (40 mg/m2) intravenously on day 1 and S-1 (80 mg/m2) on days 1-14, of a 28-day cycle. With the intraperitoneal regimen, the schedule for S-1 and cisplatin was the same. Dose escalation for docetaxel started at 30 mg/m2 (level 1). Results: Between August 2010 and July 2013, 26 consecutive patients were treated with the systemic regimen. Grade 3-4 neutropenia occurred in 81% but the toxicity profile was very tolerable. The response rate based on the Response Evaluation Criteria in Solid Tumors (RECIST) was 89%. Between April 2012 and April 2014, 5 patients with linitis plastica, large ulcero-invasive type tumors, positive washing cytology or peritoneal metastasis were enrolled in the phase I trial of the intraper itoneal regimen. Grade 3-4 elevations in aspartate/alanine aminotransferase (AST/ALT) occurred in the first 2 patients. The next 3 patients, who received docetaxel (20 mg/m2) on days 1 and 15 (level 0), had no dose-limiting toxicity. Four patients, including 3 with peritoneal metastasis and/or positive cytology before treatment, underwent R0 resection after intraperitoneal chemotherapy. Conclusion: Our studies revealed the efficacy of the systemic regimen and the safety of the intraperitoneal regimen. Further investigation of these two types of preoperative DCS chemotherapy is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84928385663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928385663&partnerID=8YFLogxK

M3 - Article

C2 - 25862882

AN - SCOPUS:84928385663

VL - 35

SP - 2223

EP - 2228

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -